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Objectives The aim of this study was to confirm prior modeling data suggesting that prasugrel 5 mg in low-body-weight
(LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight (HBW) patients as assessed by
maximal platelet aggregation (MPA).
Background Prasugrel 10 mg reduced ischemic events compared with clopidogrel 75 mg but increased bleeding, particularly
in LBW patients.
Methods In this blinded, 3-period, crossover study in stable patients with coronary artery disease (CAD) taking aspirin, prasugrel
5 and 10 mg and clopidogrel 75 mg were administered to LBW (56.4  3.7 kg; n  34) and HBW patients (84.7 
14.9 kg; n  38). Assays included light transmission aggregometry (LTA), VerifyNow P2Y12 (VN), and vasodilator-
associated stimulated phosphoprotein (VASP) level measured predose and after each 12-day treatment.
Results Median MPA by LTA for prasugrel 5 mg in LBW patients was noninferior to the 75th percentile for prasugrel 10
mg in HBW patients (primary endpoint) and mean MPA was similar, but active metabolite exposure was lowered
by 38%. Within LBW patients, prasugrel 5 mg lowered MPA more than clopidogrel (least squares mean differ-
ence [95% confidence interval]: 3.7% [6.72%, 0.69%]) and resulted in lower rates of high on-treatment
platelet reactivity (HPR). Within HBW patients, prasugrel 10 mg lowered MPA more than clopidogrel (16.9%
[22.3%, 11.5%]). Similar results were observed by VN and VASP. Prasugrel 10 mg in LBW patients was asso-
ciated with more mild to moderate bleeding (mainly bruising) compared with prasugrel 5 mg and clopidogrel.
Conclusions In aspirin-treated patients with CAD, prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar ex-
tent as prasugrel 10 mg in HBW patients and resulted in greater platelet inhibition, lower HPR, and similar
bleeding rates compared with clopidogrel. (Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus
Higher Body Weight With Coronary Artery Disease [FEATHER]; NCT01107925) (J Am Coll Cardiol 2012;60:
2032–40) © 2012 by the American College of Cardiology Foundation
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November 13, 2012:2032–40 Low-Dose Prasugrel for Low WeightThe TRITON–TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
With Prasugrel–Thrombolysis in Myocardial Infarction) study
demonstrated significantly reduced rates of ischemic events for
prasugrel compared with clopidogrel for the composite efficacy
endpoint of cardiovascular death, myocardial infarction, or
stroke in patients with acute coronary syndrome (ACS) un-
dergoing percutaneous coronary intervention (1). However,
there was an increased risk of major bleeding events in patients
treated with the 10-mg maintenance dose (MD) of prasugrel.
Analysis of TRITON–TIMI 38 data identified patients
with low body weight (LBW) (60 kg) as being at
increased risk for bleeding on the 10-mg MD (2). As a
result, a prasugrel 5-mg MD is recommended for use in
LBW patients (3,4). Additional analyses modeling prasug-
rel’s active metabolite concentrations by exposure quartiles
during 10-mg MD in a population pharmacokinetic (PK)
substudy (5) showed that higher exposure was associated
with an increased risk of bleeding, and bleeding in LBW
patients was shown to occur predominantly within the
highest 2 exposure quartiles. Furthermore, LBW patients in
the lowest 2 exposure quartiles demonstrated similar efficacy
and risk of bleeding as higher-body-weight (HBW; 60
kg) patients. On the basis of this model, it was predicted
that the prasugrel 5-mg MD in LBW patients would result
in active metabolite exposure similar to that of the lowest
quartile for the 10-mg MD—for which efficacy was main-
tained, but risk of bleeding was lowered (5).
We designed the FEATHER (Comparison of Prasugrel
and Clopidogrel in Low Body Weight Versus Higher Body
Weight With Coronary Artery Disease) trial to test the
hypothesis that in aspirin-treated patients with stable coronary
Figure 1 Study Design Diagram
*Following aspirin run-in, patients 60 kg were assigned to prasugrel 5 mg and p
domized to the alternative treatments at visit 3 and crossed over at visit 4. †Mini
and obtain consent.artery disease (CAD), the anti-
platelet effect of a prasugrel 5-mg
MD in LBW patients is noninfe-
rior to that of a prasugrel 10-mg
MD in HBW patients. The ap-
proved clopidogrel 75-mg MD
was also compared with prasugrel
5-mg and 10-mg MD by body
weight cohort.
Methods
A detailed description of the trial
design, participants, objectives
and measures, and statistical
analyses is provided in the sup-
plemental methods.
Trial design. FEATHER was
an international, multicenter,
blinded, active comparator phase
Ib trial conducted in 72 random-
ized patients with stable CAD.
The study design is illustrated in
Figure 1. The study protocol was
approved by local investigational
review boards and was performed
in compliance with the principles
of good clinical practice and in accordance with the provision
of the Declaration of Helsinki.
Participants. Patients enrolled in the FEATHER trial were
men (n 31) and women (n 41) age 18 to 75 years receiving
aspirin with a history of stable CAD. All patients provided
signed informed consent.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
AUC0–tlast  area under the
concentration curve from
time 0 to last measure
BW  body weight
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
HBW  higher body weight
HPR  high on-treatment
platelet reactivity
LBW  low body weight
MD  maintenance dose
MPA  maximal platelet
aggregation
VASP-PRI  vasodilator-
associated stimulated
phosphoprotein platelet
reactivity index
60 kg were assigned to prasugrel 10 mg (period 1). Patients were then ran-
f 10 days and maximum of 14 days on each study drug. ‡Screen for eligibilityatients
mum o
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Low-Dose Prasugrel for Low Weight November 13, 2012:2032–40Study objectives and measures. The primary objective of
FEATHER was to compare maximal platelet aggregation
(MPA) responses to 20 M adenosine diphosphate (ADP)
by light transmission aggregometry in LBW patients receiv-
ing prasugrel 5 mg versus HBW patients receiving prasugrel
10 mg (Fig. 2).
Statistical analysis. Baseline characteristics were compared
between body weight (BW) cohorts using a 2-sample t test
for continuous variables and a Pearson Chi-square test for
categorical variables.
The primary noninferiority analysis compared the median
of MPA to 20 M ADP for prasugrel 5 mg in LBW
patients with the 75th percentile of the MPA for prasugrel
10 mg in HBW patients at the end of period 1. The upper
limit of the 1-sided 97.5% confidence interval (CI) of the
difference was compared with the prespecified margin of 15
percentage points. The study had 80% power for the
Figure 2 Patient Flow Diagram
d/c  discontinued; HBW  high body weight; LBW  low body weight; SD  studnoninferiority test of the primary endpoint at a 1-sided 2.5%
significance level.
Between BW cohorts, the mean comparison for pharmaco-
dynamic (PD) parameters was conducted using analysis of
covariance. The rate of high on-treatment platelet reactivity
(HPR) was compared using the Fisher exact test. Within each
BW cohort, PD response was compared using a mixed-effect
model with repeated-measure analysis, whereas HPR was com-
pared using a generalized linear model with repeated measures.
Results
Patient disposition and baseline characteristics. Of 76
patients entering the study, 72 were enrolled and received
study drug in period 1 (Fig. 2). The majority of participants
had a history of prior myocardial infarction (58.3%), hyper-
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November 13, 2012:2032–40 Low-Dose Prasugrel for Low Weighttension (63.9%), and/or hyperlipidemia (79.2%) (Table 1).
Compared with HBW, LBW patients were more likely to
be women, to be smokers, and to have a prior history of
coronary artery bypass graft, but overall the 2 cohorts were
well matched (Table 1).
PD parameters. Responses for MPA to 20 M ADP
(Fig. 3) were not significantly different between BW cohorts
at baseline (LBW 76.3% 9.5%; HBW 77.9 12.3%; p
.53). Relative to baseline, each treatment regimen substan-
ially reduced aggregation response in both BW cohorts.
he primary endpoint of the trial demonstrated that prasu-
rel 5-mg treatment in LBW (median 47.0%) patients was
oninferior to prasugrel 10 mg (75th percentile 57.1%) in
BW patients (difference [95% CI]: 10.1% [23.4%,
.2%]). Specifically, the upper bound of the 97.5% CI for
he primary comparison was 0.20%, well below the prespeci-
ed margin of 15% for noninferiority. During period 1, the
ean MPA to 20 M ADP for LBW patients receiving
rasugrel 5 mg was not significantly different than the mean
PA in HBW patients receiving prasugrel 10 mg (least
quares mean difference [95% CI]: 5.5% [0.8%, 11.9%])
Online Table 1). In addition, in the LBW cohort, prasugrel 5
g was associated with a modestly but significantly lower
PA to 20 M ADP versus clopidogrel 75 mg (difference
3.7% [6.72%, 0.69%]). Prasugrel 10-mg treatment was
Baseline DemographicsTable 1 Baseline Demographics
Demographic LBW (n  34) HBW (n  38) p Value
Age, yrs 62.2 7.81 62.8 8.53 0.763
Male, % 5 (14.7) 26 (68.4) 0.001
Race
Caucasian, % 33 (97.1) 34 (89.5) 0.090
Black or African descent, % 0 4 (10.5)
Asian, % 1 (2.9) 0
Height, cm 161.46 (6.224) 170.44 (9.068) 0.001
Weight, kg 56.42 (3.689) 84.66 (14.884) 0.001
Mean body mass index, kg/m2 21.7 1.83 29.1 4.54 0.001
Risk factors/medical history
Current smoker [yes] 15 (44.1) 9 (23.7) 0.066
Systolic blood pressure, mm Hg 137.3 (24.30) 134.2 (17.81) 0.531
Hypertension [yes] 18 (52.9) 28 (73.7) 0.067
Hyperlipidemia [yes] 26 (76.5) 31 (81.6) 0.594
Diabetes [yes] 5 (14.7) 6 (15.8) 0.898
Prior CABG [yes] 5 (14.7) 0 (0.0) 0.014
Prior MI [yes] 19 (55.9) 23 (60.5) 0.690
Prior PCI [yes] 32 (94.1) 29 (76.3) 0.036
Comedications —
ACE inhibitors/ARBs 21 (61.8) 32 (84.2) 0.031
Diuretics 4 (11.8) 9 (23.7) 0.189
Proton pump inhibitors 12 (35.3) 11 (28.9) 0.564
Calcium-channel blockers 6 (17.6) 12 (31.6) 0.173
Beta-blockers 25 (73.5) 29 (76.3) 0.785
Statins 32 (94.1) 37 (97.4) 0.491
Values are mean  SD or n (%).
ACE angiotensin-converting enzyme; ARB angiotensin II receptor blocker; CABG coronary
rtery bypass graft; HBW  higher body weight; LBW  lower body weight; MI  myocardial
infarction; PCI  percutaneous coronary intervention; SD  standard deviation.Nssociated with a more substantial reduction in aggregation
esponse versus clopidogrel 75 mg in HBW patients (16.9%
22.3%, 11.5%]).
Aggregation responses for prasugrel 5 mg in LBW versus
rasugrel 10 mg in HBW patients (Fig. 4) were not
ignificantly different as measured by MPA to 5 M ADP,
residual platelet aggregation to 20 M ADP, inhibition of
latelet aggregation to 20 M ADP, P2Y12 reaction unit
alues, and vasodilator-associated stimulated phosphopro-
ein platelet reactivity index (VASP-PRI). Mean data for these
nd other aggregation parameters are provided in Online Table 1.
s shown in Figure 5, compared with clopidogrel 75 mg,
prasugrel 5 mg was associated with numerically greater anti-
platelet effects across the measures assessed, with some differ-
ences achieving statistical significance.
The proportion of patients exhibiting HPR was not
significantly different between LBW patients receiving pra-
sugrel 5 mg and HBW patients receiving 10 mg (Online
Table 2). In the LBW cohort, a smaller proportion of
prasugrel 5-mg patients exhibited MPA to 20 M ADP
50%, residual platelet aggregation to 5 M 14%,
erifyNow P2Y12 235 P2Y12 reaction units, and VASP-
PRI 50% compared with clopidogrel 75-mg patients, and
this difference reached statistical significance for VASP-PRI
50% (Table 2). In the HBW cohort, prasugrel 10 mg was
associated with a significantly smaller proportion of HPR
versus clopidogrel in each measure assessed, except
VerifyNow P2Y12 15%.
PK of prasugrel’s and clopidogrel’s active metabolites. In
general, exposures were higher for a given regimen in LBW
patients relative to their HBW counterparts (Fig. 6). In
patients receiving prasugrel 10 mg, the geometric mean area
under the concentration curve (AUC0–tlast) was 27% higher
n LBW versus HBW patients (59.3 vs. 46.7 ng*h/ml,
espectively). In patients receiving prasugrel 5 mg, the mean
UC0–tlast was 45% higher in LBW versus HBW patients
28.9 vs. 19.9 ng*h/ml, respectively). For the comparison
ost germane to the study’s primary objective, the geomet-
ic least squares mean AUC0–tlast for LBW patients receiv-
ng prasugrel 5 mg was 62% of that observed for HBW
atients receiving prasugrel 10 mg. As shown in Figure 6,
90% of the prasugrel active metabolite AUCs in LBW
atients receiving 5 mg fell below the median AUC in
BW patients receiving 10 mg, indicating that the reduced
osing regimen in LBW patients generally achieved active
etabolite exposures that did not exceed those in the lower
quartiles of the 10-mg MD in HBW patients. Active
etabolite exposures were also higher for prasugrel 5 mg
ersus clopidogrel 75 mg in the LBW (28.9 vs. 17.9
g*h/ml) and HBW cohorts (19.9 vs. 12.8 ng*h/ml).
afety and tolerability. Overall, for any given treatment,
BW patients experienced a higher incidence of treatment-
elated bleeding adverse events relative to HBW patients
Table 3). The majority of these events were minor contu-
ions and/or hematomas that were not clinically significant.
o drug-related bleeding events were considered severe or
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Low-Dose Prasugrel for Low Weight November 13, 2012:2032–40resulted in study drug discontinuation or withdrawal from
the trial. Bleeding-related adverse event rates were similar
following prasugrel 5-mg and clopidogrel 75-mg treatment in
LBW patients (29.4% vs. 25.0%, respectively; p  0.62) and
cross all treatment groups in HBW patients (prasugrel 5 mg
6.7%; prasugrel 10 mg 15.8%; clopidogrel 75 mg 16.2%).
iscussion
he study met the primary endpoint for noninferiority
etween prasugrel 5 mg in LBW and prasugrel 10 mg in
BW patients, with the relevant comparison falling well
elow the predefined noninferiority margin; therefore, re-
ucing the prasugrel MD from 10 mg to 5 mg did not result
n an unacceptable loss of antiplatelet effect in LBW
atients. Interestingly, we found that the 5-mg MD of
rasugrel in LBW patients resulted in similar levels
f platelet inhibition compared with the 10-mg MD in
BW patients. In addition, the 5-mg prasugrel MD in
BW patients resulted in similar rates of HPR as prasugrel
0 mg in HBW patients. Thus, in aspirin-treated patients
ith stable CAD, the prasugrel 5-mg MD in LBW patients
ad a similar platelet inhibitory effect as the 10-mg MD in
BW patients.
As predicted by previous PK/PD modeling (2), prasugrel
mg in LBW patients resulted in lower active metabolite
xposure relative to prasugrel 10 mg in HBW patients;
owever, the PD responses were not significantly different.
he similar PD responses observed were likely explained by
he previously reported nonlinear relationship between ac-
ive metabolite exposure and antiplatelet effect (6,7). The
Figure 3 MPA on Prasugrel and Clopidogrel in LBW and HBW P
(A) Overall pharmacodynamic results. (B) Primary endpoint: prasugrel 5-mg treatm
bound of the 97.5% confidence intervals for the difference between the median m
MPA in clopidogrel (Clop) 10 mg/HBW was 0.20% and thus less than the pre-spec
percentiles, and whiskers represent the 10th to 90th percentiles. The broken line
adjusted for covariates. BL  baseline; other abbreviations as in Figure 2.resent data thus suggest that the lower active metaboliteexposure generated by the prasugrel 5-mg MD is sufficient
for LBW patients to achieve adequate platelet inhibition
while potentially avoiding the risk of excessive bleeding
reported in the TRITON–TIMI 38 trial in LBW patients
receiving prasugrel 10-mg MD (2,5).
The prasugrel 5-mg MD approved for LBW patients was
also compared with the clopidogrel 75-mg MD in LBW
patients. Across platelet function measurements, prasugrel 5
mg reduced platelet activation more than clopidogrel 75 mg
in LBW patients at or near significant levels. Prasugrel 5 mg
also resulted in generally lower HPR compared with clopi-
dogrel in LBW patients, consistent with the higher active
metabolite exposures produced by prasugrel 5 mg compared
with clopidogrel 75 mg. Thus, the prasugrel 5-mg MD
offers the potential for greater clinical benefit compared with
clopidogrel 75-mg MD in LBW patients. This question is
being assessed directly in the TRILOGY-ACS (Targeted
Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes) trial com-
paring the use of prasugrel versus clopidogrel in patients
with non–ST-segment elevation ACS (8).
Although the trial was not powered for evaluation of any
clinical events, bleeding complications were closely moni-
tored. There were no major drug-related bleeding events.
Across treatments, LBW patients experienced more minor
bleeding events, such as contusions and hematomas, com-
pared with HBW patients. Prasugrel 10 mg generally
caused more bleeding events than the other 2 treatment
regimens. Prasugrel 5 mg resulted in fewer bleeding events
compared with prasugrel 10 mg and a similar event rate
ts
LBW patients was noninferior to prasugrel 10 mg in HBW patients. The upper
platelet aggregation (MPA) in prasugrel (Pras) 5 mg/LBW and 75th percentile
oninferiority margin of 15 percentage points. Boxes represent the 25th to 75th
tes high on-treatment platelet reactivity threshold (50% MPA); p values wereatien
ent in
aximal
ified n
indicacompared with clopidogrel.
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November 13, 2012:2032–40 Low-Dose Prasugrel for Low WeightThis study was limited by being a PK/PD study in a small
number of stable patients with CAD treated for a relatively
short period of time, and it was not intended to assess clinical
outcomes. In addition, the demographic data showed some
unavoidable imbalances between the 2 BW cohorts: LBW
patients were more likely to be women, to have a previous
history of coronary artery bypass graft or percutaneous coronary
intervention, to use fewer angiotensin-converting enzyme in-
Figure 4 Additional Pharmacodynamics of Prasugrel in LBW an
Platelet reactivity for prasugrel 5 mg in LBW patients versus prasugrel 10 mg in HBW
assays employed (A to H): MPA, residual platelet aggregation (RPA), inhibition of plate
stimulated phosphoprotein platelet reactivity index (VASP-PRI). Boxes represent th
broken line indicates high on-treatment platelet reactivity criteria. p Values were adjushibitor/angiotensin II receptor blocker comedications, and tobe smokers. Female sex and smoking have been associated with
altered platelet responses previously (9,10) and could have
affected platelet response to a minor extent.
In summary, prasugrel 5-mg MD treatment in LBW
patients resulted in platelet inhibition that was noninferior
compared with that of prasugrel 10-mg MD in HBW patients
and achieved active metabolite exposures in a range in which
efficacy was maintained and the risk of bleeding was lower than
W Patients
ts was not significantly different between the 2 treatment groups for any of the
gregation (IPA; by light transmission aggregometry), VerifyNow, or vasodilator-associated
to 75th percentiles, and whiskers represent the 10th to 90th percentiles. The
r covariates. PRU  P2Y12 reaction units; other abbreviations as in Figures 2 and 3.d HB
patien
let ag
e 25th
ted fothat in the TRITONTIMI 38 study (5). The PK and PD
c
c
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Low-Dose Prasugrel for Low Weight November 13, 2012:2032–40data were consistent with the lower minor bleeding rates for
prasugrel 5 mg (similar to rates for clopidogrel 75 mg)
compared with prasugrel 10 mg. These results indicate that the
prasugrel 5-mg MD could provide better risk–benefit balance
for LBW patients with CAD and support the recommended
use of the prasugrel 5-mg MD in LBW patients (3,4).
Additional randomized, controlled studies, such as the
Figure 5 Pharmacodynamics of Prasugrel 5 mg and Clopidogre
Platelet reactivity for prasugrel 5 mg and clopidogrel 75 mg within the LBW cohort. Co
antiplatelet effect across a variety of platelet function measures, several of which wer
VerifyNow, or VASP-PRI. The broken line indicates high on-treatment platelet reactivityTRILOGY-ACS trial comparing prasugrel 5-mg MD withlopidogrel 75 mg in LBW patients, are necessary to verify the
linical relevance of these results (8).
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Rates of HPR in LBW and HBW Patients Treated With Prasugrel 5Table 2 Rates of HPR in LBW and HBW Patients Treated With
HPR Definition
LBW
Prasugrel 5 mg
(n  33)
Prasugrel 10 mg
(n  32)
C
MPA to 20 M ADP 50% 14 (43.8)* 4 (12.5)
Pras 5 mg vs. Pras 10 mg 0.001
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
IPA to 20 M ADP 20% 6 (18.8) 1 (3.1)
Pras 5 mg vs. Pras 10 mg 0.041
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
RPA 5 M ADP 14% 9 (29.0) 5 (15.6)
Pras 5 mg vs. Pras 10 mg 0.083
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
VN-P2Y12 PRU 235 1 (3.1) 0
Pras 5 mg vs. Pras 10 mg NE
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
VN-P2Y12 15% 2 (6.3) 0 (0)
Pras 5 mg vs. Pras 10 mg NE
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
VASP-PRI 50% 4 (12.5) 0
Pras 5 mg vs. Pras 10 mg NE
Pras 5 mg vs. Clop 75 mg
Pras 10 mg vs. Clop 75 mg
Values are n (%).
Clop clopidogrel; HPR high on-treatment platelet reactivity; IPA inhibition of platelet aggre
units; RPA  residual platelet aggregation; VASP-PRI  vasodilator-associated stimulated phosph
Figure 6 Active Metabolite Exposure Following Prasugrel and C
Exposure to prasugrel or clopidogrel active metabolites was higher for a given trea
patients on prasugrel 5 mg had exposure levels that approximated the exposure v
10 mg (B). Boxes represent the 25th to 75th percentiles (line is the median); whi
tion curve (AUC) values from samples collected on 2 separate occasions. AbbreviaUppsala Clinical Research Center, Uppsala University
Hospital, Uppsala, Sweden; Dr. Ten Berg, Department
of Cardiology, St. Antonius, Nieuwegein, the Nether-
mg or Clopidogrel 75 mgugrel 5 or 10 mg or Clopidogrel 75 mg
HBW
grel 75 mg
 32)
Prasugrel 5 mg
(n  36)
Prasugrel 10 mg
(n  37)
Clopidogrel 75 mg
(n  36)
(58.1) 27 (77.1) 14 (37.8) 29 (82.9)
0.001
0.116 0.492
0.001 0.001
(16.1) 20 (57.1) 6 (16.2) 21 (60.0)
0.001
0.751 0.709
0.122 0.001
(46.7) 23 (65.7) 18 (48.6) 29 (82.9)
0.028
0.099 0.026
0.001 0.001
(9.4) 13 (37.1) 1 (2.9) 12 (35.3)
0.008
0.336 0.820
NE 0.010
(0) 3 (8.6) 1 (2.9) 5 (14.7)
0.333
NE 0.491
NE 0.071
(26.7) 24 (75.0) 5 (13.9) 22 (64.7)
0.001
0.04 0.255
NE 0.001
MPAmaximal platelet aggregation; NE not evaluable; Pras prasugrel; PRU P2Y12 reaction
in platelet reactivity index; other abbreviations as in Table 1.
ogrel in LBW and HBW Patients
in LBW patients relative to HBW patients (A). The majority (90%) of LBW
found in the lower 2 quartiles of exposure in the HBW cohort receiving prasugrel
represent the 10th to 90th percentiles. Data include area under the concentra-
as in Figures 2 and 3.or 10Pras
lopido
(n
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
5
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
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APPENDIX
For an expanded Methods section, and supplemental tables and references,
ed With Prasugrel 5 or 10 mg or Clopidogrel 75 mgtients Treated With Prasugrel 5 or 10 mg or Clopidogrel 75 mg
HBW
l 75 mg
32)
Prasugrel 5 mg
(n  36)
Prasugrel 10 mg
(n  38)
Clopidogrel 75 mg
(n  37)
25.0) 6, 8 (16.7) 6, 8 (15.8) 6, 8 (16.2)
3.1) 0 (0) 3, 3 (7.9) 2, 2 (5.4)
15.6) 5, 7(13.9) 3, 4 (7.9) 2, 4 (5.4)
3.1) 1, 1(2.8) 1, 1 (2.6) 2, 2 (5.4)
3.1) 0 (0) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
0) 0 (0) 0 (0) 0 (0)
lation. Patients were counted more than once if they had both mild and moderate events.TreatW Pa
idogre
(n 
8, 13 (
1, 1 (
5, 10 (
1, 1(
1, 1 (
0 (
0 (
0 (
0 (please see the online version of this article.
